Axsome Therapeutics has launched a Phase 3 trial that will assess the safety and efficacy of AXS-05, the company’s investigational oral treatment for agitation associated with Alzheimer’s disease. If positive, data from the trial is expected to support Axsome’s submission of an application requesting the therapy’s approval for treating Alzheimer’s patients with agitation. According to the company, top-line data from the study, called ACCORD, is expected in 2022. “Initiation of the ACCORD Phase 3 trial in Alzheimer’s…

You must be logged in to read/download the full post.